Reporte de un caso de Síndrome de Guillain Barré post vacuna Coronavac: ¿rol causal o asociación temporal?
- Autores: Jonathan Wimmer Del-Solar, Paulina Chávez-Martel, Estefanía Fontecilla-Villalobos, Pamela Ibáñez-Rodríguez, Juan Pablo Rozas-Vidal
- Localización: Revista Médica de Chile, ISSN-e 0034-9887, Vol. 150, Nº. 1, 2022, págs. 125-130
- Idioma: español
- Títulos paralelos:
- Guillain Barre syndrome associated with coronavac vaccine. Report of one case
- Enlaces
-
Resumen
We report a 50-year-old woman with a history of celiac disease, who presented with lumbar pain and progressive flaccid tetraparesis 48 hours after the inoculation of the first dose of CoronaVac inactivated SARS-CoV-2 vaccine. CSF was normal and electrodiagnostic studies showed an axonal motor polyneuropathy. No other triggers were identified, and other etiologies were ruled out. The presentation was compatible with the AMAN (Acute Motor Axonal Neuropathy) subtype of GBS, and intravenous immunoglobulin halted the progression of symptoms. Intensive neurorehabilitation was performed. The patient was discharged five weeks after admission, walking with poles and climbing stairs with minimal assistance. To date no cases of inactivated SARSCoV-2 vaccine related GBS have been reported. Thus, description of its clinical presentation is relevant. We discuss the current evidence relating GBS with vaccines, highlighting that vaccine associated GBS is a controversial entity and causality must be interpreted cautiously given the actual COVID-19 pandemic context.
